- Innovative Medicine
- Immunology
- Gastroenterology
Gastroenterology
Our unique clinical and research capabilities and expertise, combined with a track record of operational excellence and success, have fostered a robust, prioritized pipeline and strategy for the future. With the introduction of biologics with new mechanisms of action (MOA) and targeted oral treatments, and investment in predictive biomarkers, Johnson & Johnson remains committed to developing differentiated treatments for both patients living with IBD and healthcare professionals.
Disease areas
Newsroom
Featured resources
Can AI unlock new treatment possibilities for inflammatory bowel disease? How Johnson & Johnson is leading the way.
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
How elevating diverse GI practitioners helps patients flourish
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
A new era in treating Inflammatory Bowel Disease (IBD)
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.